In 2014, Torrent acquired the brands of Elder Pharma for Rs 2,000 crore. The Unichem deal will give it access to leading brands such as Losar, Unienzyme, Ampoxin, Telsar and Vizylac. Torrent will become among the top three players in anti-hypertensives, anti-depressants and tranquilisers.The deal is expected to add one brand of Rs 200 crore and three brands of more than Rs 50 crore to Torrent’s portfolio. It is also expected to realise cost and revenue synergies in Torrent’s branded business in India,” Torrent Pharma chairman Samir Mehta said in a statement on Friday. “We will see that going forward it would be domestic companies who would be acquiring their peers,” Shah told ET.India’s domestic pharma market is no longer an attractive acquisition target for multinational drugmakers who want to expand their generic foothold.

Source: Economic Times November 03, 2017 12:18 UTC